Gilead Seeks Approval for Trodelvy in Advanced Breast Cancer Treatment
Gilead Sciences, headquartered in Chiyoda, Tokyo, has recently filed for an additional approval of Trodelvy (sacituzumab govitecan) for the treatment of patients with hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer who have a history of chemotherapy. This new indication aims to expand Trodelvy's use in adults suffering from unresectable or recurrent breast cancer, following its prior approval for a different patient group in September of last year.
Trodelvy is an antibody-drug conjugate (ADC) that targets the TROP-2 protein and has received global recognition, already approved in over 50 countries, including Japan. Its effectiveness has been documented in multiple clinical trials, including the international Phase III trial (TROPiCS-02) and the domestic Phase II trial (ASCENT-J02). These trials focused on patients who had undergone multiple chemotherapy treatments and had metastatic breast cancer that demonstrated resistance to endocrine therapies and chemotherapy agents.
The hormone receptor-positive and HER2-negative type of breast cancer constitutes around 75% of all breast cancer cases, making it the most prevalent subtype. Patients with advanced HR+/HER2- breast cancer often find the primary treatment option limited to chemotherapy, particularly if they exhibit resistance to endocrine therapies. This underscores the critical need for innovative treatment options to better manage this challenging condition, particularly considering that many patients will have undergone the therapy with multiple chemotherapeutics.
Trodelvy has already become a vital part of the treatment landscape for adults living with HR+/HER2- metastatic and recurrent breast cancer, approved for use in numerous regions worldwide including the United States, the UK, the European Union, Canada, and Australia. As Gilead seeks an additional approval for Trodelvy targeting a broader patient population, it may represent an important milestone in the fight against breast cancer.
Founded over 30 years ago, Gilead Sciences has consistently worked towards achieving a healthier world by pursuing medical innovation. The company focuses its research and development efforts on life-threatening diseases like HIV, viral hepatitis, COVID-19, and cancer. With its headquarters in Foster City, California, Gilead supports operations in over 35 countries globally, striving to improve treatment options for those in need. Their ongoing commitment to furthering medical advancement maintains Gilead as a key player in the pharmaceutical industry and a beacon of hope for patients battling critical conditions.
As healthcare continues to evolve, the approval of Trodelvy may signal progress in creating better therapeutic strategies for battling advanced breast cancer, ultimately aiming to improve patient outcomes and prolong lives. Gilead's efforts reflect a growing understanding and response to the complexities associated with breast cancer treatments and patient care, emphasizing the need for personalized and innovative solutions in oncology.
With changes anticipated in the treatment protocol for HR+/HER2- breast cancer, healthcare providers and patients alike look forward to the potential benefits that Trodelvy could deliver. Its anticipated approval could offer renewed hope and options for managing advanced stages of this prevalent type of breast cancer, reaffirming Gilead's role in advancing cancer care and management for complex patient needs.
Trodelvy is an antibody-drug conjugate (ADC) that targets the TROP-2 protein and has received global recognition, already approved in over 50 countries, including Japan. Its effectiveness has been documented in multiple clinical trials, including the international Phase III trial (TROPiCS-02) and the domestic Phase II trial (ASCENT-J02). These trials focused on patients who had undergone multiple chemotherapy treatments and had metastatic breast cancer that demonstrated resistance to endocrine therapies and chemotherapy agents.
The hormone receptor-positive and HER2-negative type of breast cancer constitutes around 75% of all breast cancer cases, making it the most prevalent subtype. Patients with advanced HR+/HER2- breast cancer often find the primary treatment option limited to chemotherapy, particularly if they exhibit resistance to endocrine therapies. This underscores the critical need for innovative treatment options to better manage this challenging condition, particularly considering that many patients will have undergone the therapy with multiple chemotherapeutics.
Trodelvy has already become a vital part of the treatment landscape for adults living with HR+/HER2- metastatic and recurrent breast cancer, approved for use in numerous regions worldwide including the United States, the UK, the European Union, Canada, and Australia. As Gilead seeks an additional approval for Trodelvy targeting a broader patient population, it may represent an important milestone in the fight against breast cancer.
Founded over 30 years ago, Gilead Sciences has consistently worked towards achieving a healthier world by pursuing medical innovation. The company focuses its research and development efforts on life-threatening diseases like HIV, viral hepatitis, COVID-19, and cancer. With its headquarters in Foster City, California, Gilead supports operations in over 35 countries globally, striving to improve treatment options for those in need. Their ongoing commitment to furthering medical advancement maintains Gilead as a key player in the pharmaceutical industry and a beacon of hope for patients battling critical conditions.
As healthcare continues to evolve, the approval of Trodelvy may signal progress in creating better therapeutic strategies for battling advanced breast cancer, ultimately aiming to improve patient outcomes and prolong lives. Gilead's efforts reflect a growing understanding and response to the complexities associated with breast cancer treatments and patient care, emphasizing the need for personalized and innovative solutions in oncology.
With changes anticipated in the treatment protocol for HR+/HER2- breast cancer, healthcare providers and patients alike look forward to the potential benefits that Trodelvy could deliver. Its anticipated approval could offer renewed hope and options for managing advanced stages of this prevalent type of breast cancer, reaffirming Gilead's role in advancing cancer care and management for complex patient needs.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.